Selleck Chemicals supplies over 3,000 inhibitors used in the study of cell signaling pathways. We actively tracks the latest science so our customers can rely on us to be the leading supplier of the newest inhibitors.
Company WebsiteZINC05007751 is a potent NIMA-related kinase NEK6 inhibitor with an IC50 of 3.4 μM, shows antiproliferative activity against a panel of human cancer cell lines and displays a synergistic effect with Cisplatin and Paclitaxel in a BRCA2 mutated ovarian cancer cell line.
More Information Supplier PageZINC05007751 is a potent NIMA-related kinase NEK6 inhibitor with an IC50 of 3.4 μM, shows antiproliferative activity against a panel of human cancer cell lines and displays a synergistic effect with Cisplatin and Paclitaxel in a BRCA2 mutated ovarian cancer cell line.
More Information Supplier PageZingiberis Rhizoma Extract is extracted from Zingiber officinale, which has pharmacological effects on the nervous system, cardiovascular and cerebrovascular systems, as well as antiemetic, antibacterial, antitumor, anti-inflammatory, and antioxidant effects.
More Information Supplier PageZingibroside R1, isolated from rhizomes of Panax zingiberensis Wu et Feng (Araliaceae), has some anti-HIV-1 activity. Zingibroside R1 shows the inhibitory effects on the 2-deoxy-D-glucose (2-DG) uptake by EAT cells with IC50 of 91.3 µM and the growth of MT-4 cells with CC50 of 46.2 µM.
More Information Supplier PageZIP is a novel, cell-permeable protein kinase Mζ(PKMζ) inhibitor that blocks PKMζ-mediated synaptic potentiation.
More Information Supplier PageZIP is a novel, cell-permeable protein kinase Mζ(PKMζ) inhibitor that blocks PKMζ-mediated synaptic potentiation.
More Information Supplier Pagezipalertinib (TAS6417) is a novel EGFR inhibitor that targets EGFR exon 20 insertion mutations while sparing wild-type (WT) EGFR. IC50 values ranges from 1.1 ± 0.1 to 8.0 ± 1.1 nmol/L.
More Information Supplier Pagezipalertinib (TAS6417) is a novel EGFR inhibitor that targets EGFR exon 20 insertion mutations while sparing wild-type (WT) EGFR. IC50 values ranges from 1.1 ± 0.1 to 8.0 ± 1.1 nmol/L.
More Information Supplier PageZiprasidone HCl (CP-88059) is a novel and potent dopamine and serotonin (5-HT) receptor antagonist, used in the treatment of schizophrenia and bipolar disorder.
More Information Supplier PageZiprasidone HCl (CP-88059) is a novel and potent dopamine and serotonin (5-HT) receptor antagonist, used in the treatment of schizophrenia and bipolar disorder.
More Information Supplier PageZiritaxestat (GLPG1690) is a selective autotaxin inhibitor with an IC50 of 131 nM and Ki of 15 nM.
More Information Supplier PageZiritaxestat (GLPG1690) is a selective autotaxin inhibitor with an IC50 of 131 nM and Ki of 15 nM.
More Information Supplier PageZiritaxestat (GLPG1690) is a selective autotaxin inhibitor with an IC50 of 131 nM and Ki of 15 nM.
More Information Supplier PageZiritaxestat (GLPG1690) is a selective autotaxin inhibitor with an IC50 of 131 nM and Ki of 15 nM.
More Information Supplier PageZiyuglycoside I is one of the major active ingredients in Sanguisorba officinalis and could be used as an active ingredient for cosmetics.
More Information Supplier PageZiyuglycoside I is one of the major active ingredients in Sanguisorba officinalis and could be used as an active ingredient for cosmetics.
More Information Supplier PageZiyuglycoside II is an active compound of Sanguisorba officinalis L. that has anti-inflammation, antioxidation, antibiosis, and homeostasis properties.
More Information Supplier PageZK53 is a selective activator of mitochondrial caseinolytic protease P (HsClpP). It exhibits an EC50 of 1.37 μM for α-casein hydrolysis by HsClpP. ZK53 treatment allosterically activates HsClpP to uncontrollably degrade the essential mitochondrial proteins and is inactive toward bacterial ClpP proteins.
More Information Supplier PageZK53 is a selective activator of mitochondrial caseinolytic protease P (HsClpP). It exhibits an EC50 of 1.37 μM for α-casein hydrolysis by HsClpP. ZK53 treatment allosterically activates HsClpP to uncontrollably degrade the essential mitochondrial proteins and is inactive toward bacterial ClpP proteins.
More Information Supplier PageZK53 is a selective activator of mitochondrial caseinolytic protease P (HsClpP). It exhibits an EC50 of 1.37 μM for α-casein hydrolysis by HsClpP. ZK53 treatment allosterically activates HsClpP to uncontrollably degrade the essential mitochondrial proteins and is inactive toward bacterial ClpP proteins.
More Information Supplier PageZK53 is a selective activator of mitochondrial caseinolytic protease P (HsClpP). It exhibits an EC50 of 1.37 μM for α-casein hydrolysis by HsClpP. ZK53 treatment allosterically activates HsClpP to uncontrollably degrade the essential mitochondrial proteins and is inactive toward bacterial ClpP proteins.
More Information Supplier PageZK756326 is a full agonist of CCR8（Chemokine receptor 8） with an IC50 of 1.8 μM, dose-responsively eliciting an increase in intracellular calcium and cross-desensitizing the response of the receptor to CCL1.
More Information Supplier PageZK824859 is a potent, selective and orally bioavailable inhibitor of urokinase plasminogen activator (uPA) with IC50 of 79 nM, 1580 nM and 1330 nM for human uPA, tPA, and plasmin, respectively.
More Information Supplier PageZK824859 is a potent, selective and orally bioavailable inhibitor of urokinase plasminogen activator (uPA) with IC50 of 79 nM, 1580 nM and 1330 nM for human uPA, tPA, and plasmin, respectively.
More Information Supplier PageZL0420 is a potent and selective BRD4 inhibitor with IC50 values of 27 nM against BRD4 BD1 and 32 nM against BRD4 BD2 respectively and good selectivity over that of the related BRD2 homolog.
More Information Supplier PageZL0420 is a potent and selective BRD4 inhibitor with IC50 values of 27 nM against BRD4 BD1 and 32 nM against BRD4 BD2 respectively and good selectivity over that of the related BRD2 homolog.
More Information Supplier PageZLc-002 is a selective inhibitor of nNOS-Capon coupling. ZLc-002 suppresses inflammatory nociception and chemotherapy-induced neuropathic pain.
More Information Supplier PageZLc-002 is a selective inhibitor of nNOS-Capon coupling. ZLc-002 suppresses inflammatory nociception and chemotherapy-induced neuropathic pain.
More Information Supplier PageZLN005 is a potent and tissue-specific PGC-1α transcriptional activator.
More Information Supplier PageZLN005 is a potent and tissue-specific PGC-1α transcriptional activator.
More Information Supplier PageZLN005 is a potent and tissue-specific PGC-1α transcriptional activator.
More Information Supplier PageZM 306416 (CB 676475) is a VEGFR (Flt and KDR) inhibitor for VEGFR1 with IC50 of 0.33 μM, but also found to inhibit EGFR with IC50 of
More Information Supplier PageZM 306416 (CB 676475) is a VEGFR (Flt and KDR) inhibitor for VEGFR1 with IC50 of 0.33 μM, but also found to inhibit EGFR with IC50 of
More Information Supplier PageZM 336372 (Zinc00581684) is a potent and selective c-Raf inhibitor with IC50 of 70 nM, 10-fold selectivity over B-RAF, no inhibition to PKA/B/C, AMPK, p70S6, etc.
More Information Supplier PageZM 39923 HCl is an JAK1/3 inhibitor with pIC50 of 4.4/7.1, almost no activity to JAK2 and modestly potent to EGFR; also found to be sensitive to transglutaminase.
More Information Supplier PageZM 447439 is a selective and ATP-competitive inhibitor for Aurora A and Aurora B with IC50 of 110 nM and 130 nM, respectively. It is more than 8-fold selective for Aurora A/B than MEK1, Src, Lck and has little effect against CDK1/2/4, Plk1, Chk1, etc.
More Information Supplier PageZM 447439 is a selective and ATP-competitive inhibitor for Aurora A and Aurora B with IC50 of 110 nM and 130 nM, respectively. It is more than 8-fold selective for Aurora A/B than MEK1, Src, Lck and has little effect against CDK1/2/4, Plk1, Chk1, etc.
More Information Supplier PageZM 447439 is a selective and ATP-competitive inhibitor for Aurora A and Aurora B with IC50 of 110 nM and 130 nM, respectively. It is more than 8-fold selective for Aurora A/B than MEK1, Src, Lck and has little effect against CDK1/2/4, Plk1, Chk1, etc.
More Information Supplier PageZM 447439 is a selective and ATP-competitive inhibitor for Aurora A and Aurora B with IC50 of 110 nM and 130 nM, respectively. It is more than 8-fold selective for Aurora A/B than MEK1, Src, Lck and has little effect against CDK1/2/4, Plk1, Chk1, etc.
More Information Supplier PageZM-241385 is a high affinity antagonist ligand selective for the adenosine A2A receptor.
More Information Supplier PageZM-241385 is a high affinity antagonist ligand selective for the adenosine A2A receptor.
More Information Supplier PageZM-241385 is a high affinity antagonist ligand selective for the adenosine A2A receptor.
More Information Supplier PageZofenopril calcium (SQ-26991) is an angiotensin-converting enzyme (ACE) inhibitor that protects the heart and helps reduce high blood pressure.
More Information Supplier PageZofenopril calcium (SQ-26991) is an angiotensin-converting enzyme (ACE) inhibitor that protects the heart and helps reduce high blood pressure.
More Information Supplier PageZolbetuximab (Anti-CLDN18.2) is a monoclonal antibody targeting Claudin-18.2. It can be used for the research of gastrointestinal adenocarcinomas and pancreatic tumors. MW :150 KD.
More Information Supplier Page
